FDA Warned Four Peptide Sellers at Once: What the September 2026 Letters Actually Say
FDA's four September 2026 peptide seller warning letters show why research-only disclaimers did not outweigh human-drug claims, bacteriostatic water, guides, calculators, and other injection-related sales context.
FDA Warned Four Peptide Sellers at Once: What the September 2026 Letters Actually Say
The four FDA peptide warning letters posted September 1, 2026 make the same central allegation: “research use only” disclaimers did not outweigh website claims and sales context that, in FDA’s view, showed the products were intended as drugs for human use. FDA identified specific products as unapproved new drugs and treated injection-adjacent items—especially bacteriostatic water, guides, and calculators—as additional evidence of intended use.
The letters were issued August 24 to Peptide Partners LLC, NuScience Peptides LLC, TXP Innovations LLC dba Tex Peptides, and Royal Peptides LLC. FDA’s public list shows all four were posted September 1 and categorized as “Unapproved New Drugs/Misbranded.”
These are warning letters, not court judgments. They state FDA’s concerns, request corrective responses, and give recipients an opportunity to disagree and provide supporting information. They do not prove that every peptide seller, every product with the same named molecule, or every compounding situation has the same regulatory status.
Educational note: This article is general regulatory education. It is not legal advice, medical advice, buying guidance, sourcing guidance, dosing guidance, reconstitution guidance, or a recommendation to use any product.
The letters repeatedly connect product claims, disclaimers, and injection-adjacent sales context. The whole presentation—not one phrase in isolation—drove FDA’s intended-use analysis.
Quick answer: what did the four FDA peptide warning letters allege?
FDA alleged that each website marketed particular products as drugs for human use and sold those products without an approved application in effect. Across the letters, the agency relied on two linked kinds of evidence:
- Claims about effects on disease, health, or body function. FDA quoted product pages discussing weight loss, blood sugar, obesity, diabetes, sexual function, liver health, mitochondrial function, tissue repair, inflammation, and other human outcomes.
- The surrounding sales context. FDA pointed to bacteriostatic water marketed with peptide products, and in two letters to a peptide calculator or guide, as evidence that the sites provided means to prepare injectable products for human administration.
Every letter also included the same public-health warning: injectable products can cause serious harm because they enter the body directly and bypass some key defenses against toxins and microorganisms.
The allegation was therefore not “the disclaimer used the wrong words.” It was that the broader website presentation contradicted the disclaimer.
Which products and patterns appeared across the four letters?
Five named molecule groups appeared in all four letters: semaglutide, tirzepatide, retatrutide, tesamorelin, and PT-141/bremelanotide. SS-31/elamipretide appeared in three. Bacteriostatic water appeared either as a product FDA classified as a drug or as contextual evidence in all four.
| Product or marketing feature | Pattern across the letters | What FDA focused on |
|---|---|---|
| Semaglutide | Named by all four | Claims about glucose regulation, weight loss, metabolism, cardiovascular or other human-health effects |
| Tirzepatide | Named by all four | Claims about blood sugar, appetite, weight management, obesity, and metabolic health |
| Retatrutide | Named by all four | Claims about triple-receptor activity, weight loss, glucose control, lipids, liver health, or related metabolic outcomes |
| SS-31 / elamipretide | Peptide Partners, Tex Peptides, Royal Peptides | Claims about mitochondrial function, oxidative stress, cellular energy, retinal or liver effects, and anti-aging or neuroprotection themes |
| Tesamorelin | Named by all four, including blends on two sites | Claims about GH/IGF-1 signaling, visceral fat, liver health, muscle, cognition, body composition, or recovery |
| PT-141 / bremelanotide | Named by all four | Claims about sexual function, desire, arousal, libido, or central nervous system effects |
| Bacteriostatic water | Named as an unapproved product in three letters; cited as context in Royal’s footnote | Sale alongside injectable peptide products as a solvent or preparation aid |
| Peptide guides and calculators | Explicitly cited for NuScience and Royal | Resources that FDA said helped provide the means to prepare an injectable drug for human administration |
NuScience’s letter also named survodutide, mazdutide, and a tesamorelin–ipamorelin blend. Royal’s named list included “BIMORELIN,” described on the cited site as a tesamorelin–ipamorelin blend. The letters were not inventories of every product sold on each site; FDA repeatedly said the cited violations were not necessarily all-inclusive.
Why did “research use only” disclaimers not end the analysis?
FDA treated intended use as a context question, not a keyword test. Each letter included a footnote acknowledging the site’s research-only or not-for-human-use wording and then explaining why FDA believed other evidence established intended human-drug use.
That evidence included:
- product-page statements about treating, improving, mitigating, or affecting human health conditions or body functions;
- comparisons with known medicines or clinical outcomes;
- consumer-facing descriptions of weight loss, libido, metabolic health, liver health, or recovery;
- bacteriostatic water sold beside products presented as injectable;
- calculators or guides connected to preparing those products.
This is the same distinction explained in PeptideBase’s guide to research use only peptide labels: a disclaimer is one piece of evidence. It does not erase the rest of a page.
Answer block: Does a research-only disclaimer prevent FDA from treating a product as a drug?
Not automatically. In these four letters, FDA said the cited claims and injection-related sales context established intended human-drug use despite the disclaimers.
What does “unapproved new drug” mean in these letters?
FDA’s conclusion was product-specific: no approved application was in effect for the particular products it reviewed under the conditions promoted on those sites. The letters said those products were “new drugs” because they were not generally recognized as safe and effective for the uses suggested in their labeling, and that introducing them into interstate commerce without an approved application violated the Federal Food, Drug, and Cosmetic Act.
That wording must not be flattened into “the molecule name is always unapproved.” Drug approval attaches to a specific application, product, formulation, manufacturer, labeling, and indication.
| Molecule name seen in the letters | Separate FDA-reviewed product context | Why the distinction matters |
|---|---|---|
| Semaglutide | FDA-approved semaglutide products exist, including products sold under Ozempic, Rybelsus, and Wegovy labeling | Approval of those products does not transfer to an online vial labeled “semaglutide” |
| Tirzepatide | FDA-approved tirzepatide products exist under Mounjaro and Zepbound labeling | The approved application covers the reviewed product and labeling, not every product using the ingredient name |
| Retatrutide | The four letters said no approved application was in effect for the reviewed retatrutide products | Clinical-study interest does not itself create an approved product |
| Elamipretide | FDA approved Forzinity (elamipretide hydrochloride) under accelerated approval for improving muscle strength in adults and pediatric patients with Barth syndrome weighing at least 30 kg | A seller’s “SS-31” vial and broad mitochondrial or anti-aging claims are not the same product or indication |
| Tesamorelin | Egrifta products have specific FDA labeling for reducing excess abdominal fat in adults with HIV and lipodystrophy | That narrow product history does not validate generic body-composition, liver, cognition, or blend claims |
| Bremelanotide | Vyleesi is specifically labeled for certain premenopausal women with acquired, generalized hypoactive sexual desire disorder | A generic “PT-141” product marketed for libido or sexual enhancement is not automatically Vyleesi |
| Bacteriostatic water | Approved sterile diluent products may exist in defined applications | A seller’s water product does not inherit another manufacturer’s approval, and context may establish its intended drug use |
Current FDA product records support these product-level distinctions for elamipretide, bremelanotide, tesamorelin, semaglutide, and tirzepatide. The records identify approved applications and products; they do not authenticate products sold elsewhere under similar names.
For a broader explanation, see GLP-1 Peptides vs Research Peptides and PeptideBase’s tesamorelin evidence review.
Why did FDA emphasize injection risk?
FDA emphasized injection because route changes the consequence of contamination and product-quality failure. All four letters use nearly identical language: injectable drug products are delivered directly into the body, sometimes into the bloodstream, and bypass key defenses against toxins and microorganisms.
That concern is wider than the pharmacology of semaglutide, SS-31, or any other peptide. It includes questions such as:
- whether the product is sterile;
- whether the labeled concentration and identity are accurate;
- whether contamination or endotoxin is present;
- whether packaging and storage preserve product quality;
- whether the preparation context creates additional error or contamination risk.
The letters did not provide lab-test results proving that every named vial was contaminated. FDA’s point was that the injectable route raises the public-health stakes when products are unapproved and their safety, effectiveness, and quality have not been reviewed through an approved application.
What do the letters say about bacteriostatic water, guides, and calculators?
FDA treated these items as evidence about how the products were meant to be used. Peptide Partners and Tex Peptides were cited for selling bacteriostatic water as a solvent for products FDA regarded as intended for injection. NuScience’s footnote cited bacteriostatic water alongside a peptide calculator. Royal’s cited bacteriostatic water alongside a peptide guide and calculator.
This matters because intended use can arise from a product ecosystem. A page may say “not for human use,” while the surrounding store supplies the product, the preparation liquid, and a calculation tool. FDA read those pieces together.
This article intentionally does not reproduce any calculator inputs, preparation steps, volumes, concentrations, or reconstitution instructions.
What happens after an FDA warning letter?
A warning letter gives the recipient notice of FDA’s concerns and an opportunity to respond; it is not necessarily the final interaction. Each of these letters requested a written response within 15 business days, including corrective steps, recurrence-prevention measures, and supporting documentation. The recipients were also invited to submit information they believed showed their products were not in violation.
FDA’s warning and close-out letter explainer says:
- a warning letter identifies what FDA believes are significant violations;
- the recipient can address or dispute those concerns;
- later communications or actions may change the regulatory status of the issues;
- FDA may issue a close-out letter after evaluating and verifying adequate corrective action;
- future inspection or enforcement can still occur if violations continue or recur.
The letters also warn that failure to address violations may result in regulatory or legal action, including seizure or injunction. That is a stated enforcement possibility, not proof that such action has already happened in any of these four cases.
Answer block: Are the September 2026 letters final proof of liability?
No. They are formal statements of FDA’s concerns and requested corrections. Recipients can respond, and later interactions or close-out actions can change the public regulatory record.
What these four letters do not prove
The letters support a strong pattern finding, but not a universal conclusion about every peptide-related product. They do not prove:
- that every peptide seller uses the same marketing or sales context;
- that every product bearing one of these molecule names is the same product;
- that an approved medicine becomes unapproved because a different seller used the same active-ingredient name;
- that every compounded preparation has the same status as the products reviewed in these letters;
- that every vial named in a letter was contaminated;
- that every scientific statement about a named molecule is unlawful;
- that the recipients have exhausted their opportunity to respond;
- that FDA has already obtained a court order or completed every possible enforcement step.
Compounding is especially fact-specific. Product identity, patient need, prescription context, pharmacy status, bulk substance rules, and compliance with applicable federal and state requirements can all matter. PeptideBase’s FDA peptide compounding review explains one of those narrower regulatory pathways. Neither that article nor this one is legal advice.
A practical way to read future FDA peptide warning letters
Read the exact product, exact claims, exact sales context, and exact stage of the process before generalizing. A useful five-question check is:
- What specific product did FDA review? Do not substitute a molecule name for a finished product.
- What claims established intended use? Separate quoted website language from the article author’s interpretation.
- What surrounding tools or products mattered? Look for solvents, guides, calculators, or other human-use cues.
- What did FDA actually conclude? Warning letter, close-out letter, recall, seizure, injunction, and approval action are different events.
- Has the public record changed? FDA warns that later interaction may change the regulatory status of issues described in a letter.
This method is also useful beyond peptides. It stops a regulatory document from turning into either seller panic or a loophole-hunting exercise. For a broader evidence checklist, read How to Evaluate Peptide Claims Online.
Bottom line
The September 2026 FDA peptide warning letters show a coordinated, recurring theory of intended use: research-only disclaimers did not control when product claims and injection-adjacent sales context pointed toward human-drug use. FDA treated multiple named products as unapproved new drugs and highlighted the added public-health concern of injectable products.
The right conclusion is narrow. The letters concern specific websites, specific products, specific claims, and the context FDA reviewed in July 2026. They do not erase approved product applications for semaglutide, tirzepatide, elamipretide, tesamorelin, or bremelanotide. They also do not decide every compounding scenario or every future enforcement outcome.
The durable lesson is regulatory literacy: disclaimers, molecule names, product approval, intended use, route, and process stage are separate questions. The four letters matter because FDA read them together.
FAQ
When were the four FDA peptide warning letters posted?
FDA’s warning-letter list shows they were issued August 24, 2026 and posted September 1, 2026.
Which companies received the letters?
Peptide Partners LLC, NuScience Peptides LLC, TXP Innovations LLC dba Tex Peptides, and Royal Peptides LLC.
Did FDA say research-only disclaimers never matter?
No. FDA said that, in these cases, other website evidence established intended human-drug use despite the disclaimers. The analysis was contextual.
Are semaglutide and tirzepatide FDA-approved?
Specific semaglutide and tirzepatide drug products have FDA-approved applications and labeling. That does not mean every product advertised under either ingredient name is approved or equivalent to an approved product.
Is retatrutide FDA-approved?
The four letters state that no approved application was in effect for the retatrutide products FDA reviewed. This article does not infer approval from clinical-trial or research interest.
Did the letters prove the products were contaminated?
No. The letters emphasized the heightened risk of injectable products and classified named products as unapproved new drugs. They did not report testing that proved every named product was contaminated.
Are warning letters final enforcement judgments?
No. FDA describes warning letters as notices of concerns that request a response. Later corrections, disagreement, FDA evaluation, close-out letters, or additional enforcement may change the record.